ERAS
HealthcareErasca, Inc. · Biotechnology · $4B
What is Erasca, Inc.?
Erasca, Inc. is a clinical-stage biopharmaceutical company built around a single scientific focus: dismantling the RAS/MAPK signaling pathway, one of the most frequently mutated drivers of human cancer. Headquartered in San Diego, the company is advancing a pipeline of targeted oral therapies.
Erasca discovers and develops oral therapies aimed at cancers driven by the RAS/MAPK pathway — a network of proteins that, when mutated, fuels tumor growth across many cancer types. The company does not yet generate product revenue; it funds operations through capital markets while advancing candidates through clinical trials. Its strategy centers on targeting multiple nodes within this pathway simultaneously, an approach designed to overcome the resistance mechanisms that have historically limited single-agent treatments in this space.
Erasca was incorporated in 2018 and is headquartered in San Diego, California.
- ERAS-007 — oral ERK1/2 inhibitor for lung, colorectal, and blood cancers
- ERAS-601 — oral SHP2 inhibitor for advanced or metastatic solid tumors
- ERAS-801 — CNS-penetrant EGFR inhibitor for recurrent glioblastoma
Is ERAS a Good Stock to Buy?
UQS Score rates ERAS as Poor overall, reflecting the realities of its early-stage clinical profile.
Among the five pillars, Risk stands out as the relative bright spot — a notable distinction for a pre-revenue biotech, suggesting the balance sheet carries a degree of runway that provides some near-term stability. This is meaningful context for investors evaluating clinical-stage names.
Quality, Moat, Growth, and Valuation all register as weak or elevated, consistent with a company that has no approved products, no commercial revenue, and a market price that already reflects significant pipeline optionality.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ERAS pay dividends?
No — Erasca, Inc. does not currently pay a dividend.
Erasca does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward funding research, clinical trials, and pipeline development. Income-focused investors should look elsewhere; those evaluating ERAS are typically doing so on the basis of pipeline potential rather than current cash returns.
When does ERAS report earnings?
Erasca reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, Erasca's quarterly reports center on cash burn, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Key items to watch include pipeline milestone updates and changes to the cash runway.
For the most recent quarter's results and pipeline updates, visit Erasca's investor relations page directly.
ERAS Price History
+6.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Erasca, Inc.?
Based on Erasca, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ERAS Long-term Outlook
Erasca's fundamental outlook is shaped almost entirely by clinical trial outcomes rather than near-term financial performance. The Growth pillar registers as Weak, reflecting the absence of approved products and the binary nature of drug development timelines. The Risk pillar offers a relative counterbalance, suggesting the company retains enough financial footing to continue operations through near-term trial readouts. Valuation is rated Elevated, meaning the current market price embeds meaningful expectations for pipeline success — a dynamic that creates asymmetric risk if trials disappoint.
Growth drivers
- Potential clinical data readouts across the ERAS-007, ERAS-601, and ERAS-801 programs
- Growing scientific and commercial interest in RAS/MAPK pathway inhibition across oncology
- Possible partnership or licensing activity as pipeline assets mature
Key risks
- Clinical trial failure or disappointing efficacy data for any lead candidate
- Ongoing cash burn with no product revenue to offset operating expenses
- Elevated valuation leaves limited margin of safety if pipeline progress stalls
ERAS vs Peers
Erasca operates in a crowded clinical-stage oncology space alongside other pre-revenue biotechs pursuing targeted cancer therapies.
Celcuity focuses on CDK4/6 pathway combinations in breast cancer, targeting a different oncology mechanism than Erasca's RAS/MAPK approach.
Centessa operates a multi-asset platform model spanning several disease areas, offering broader pipeline diversification compared to Erasca's focused RAS/MAPK strategy.
Immunovant targets autoimmune diseases through FcRn inhibition, representing a distinct therapeutic area and mechanism relative to Erasca's oncology pipeline.
Frequently Asked Questions
What does Erasca do?
Erasca is a clinical-stage biopharmaceutical company focused on developing oral therapies for cancers driven by the RAS/MAPK signaling pathway. Its pipeline includes candidates targeting ERK1/2, SHP2, and EGFR — proteins frequently mutated in lung, colorectal, blood, and brain cancers. The company has no approved products and does not yet generate product revenue.
Does ERAS pay dividends?
No, Erasca does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and clinical operations. Investors in ERAS are generally seeking pipeline-driven appreciation rather than income.
When does ERAS report earnings?
Erasca reports on a quarterly cadence, as required for US-listed public companies. Because it is pre-revenue, reports focus on cash position and trial updates rather than traditional earnings metrics. Check Erasca's investor relations page for the current reporting schedule.
Is ERAS a good stock to buy?
UQS Score rates ERAS as Poor overall. The score reflects weak readings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. The Risk pillar is the relative standout. Whether ERAS fits a portfolio depends on an investor's tolerance for clinical-stage binary risk. View the full pillar breakdown on UQS Pro.
Is ERAS overvalued?
UQS Score assigns an Elevated Valuation label to ERAS, indicating the current market price reflects significant optimism about pipeline outcomes. For a pre-revenue company, valuation is largely a function of clinical probability — meaning any trial setback can have an outsized impact on the stock.
How does ERAS compare to its competitors?
Erasca is narrowly focused on RAS/MAPK pathway oncology, which differentiates it from peers like Centessa, which runs a diversified multi-asset platform, and Immunovant, which operates in autoimmune disease. Celcuity targets breast cancer via a different pathway. Each company carries its own clinical and financial risk profile.
What is ERAS's market cap bracket?
Erasca is classified as a mid-cap company. This places it in a range that typically attracts both institutional and retail investor attention, though for a clinical-stage biotech, market cap reflects pipeline expectations rather than current business scale.
Who founded Erasca?
Erasca was incorporated in 2018 and is headquartered in San Diego, California. Founding and leadership details are publicly available through the company's official website and SEC filings for those seeking a complete history.
Is ERAS a long-term quality investment?
As a long-term quality indicator, UQS Score currently rates ERAS as Poor. The absence of approved products, weak moat characteristics, and elevated valuation create a challenging quality profile. Long-term outcomes for clinical-stage biotechs hinge on trial success, which remains inherently uncertain. Pro members can access the complete pillar analysis.
What is the main competitive advantage of Erasca?
Erasca's scientific differentiation lies in its focus on multiple nodes within the RAS/MAPK pathway simultaneously — a strategy intended to address the resistance mechanisms that have limited single-target approaches. However, UQS Score currently rates the Moat pillar as Weak, reflecting that this advantage is unproven in a commercial context.
What sector does ERAS belong to?
Erasca operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) to compare quality profiles across the sector.
Unlock Full ERAS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access full financial metrics and trend data
- ✓Compare ERAS against peers on a normalized basis
- ✓Track pipeline-stage risk through the Risk pillar detail
- ✓Get the complete analyst view available to Pro members
Pro Analysis
ERAS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 17.7 | 0.0 | 11.0 | 18.5 | 75.2 | 0.0 | +4.0 |
| May 9, 2026 | 13.7 | 0.0 | 11.0 | 0.0 | 73.3 | 0.0 | -3.7 |
| Apr 22, 2026 | 17.4 | 0.0 | 11.0 | 18.5 | 73.3 | 0.0 | -1.0 |
| Apr 2, 2026 | 18.4 | 0.0 | 11.0 | 23.1 | 73.3 | 0.0 | — |
ERAS — Pillar Breakdown
Quality
— 0.0/100 (25%)Erasca, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Erasca, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 75.2/100 (15%)Erasca, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Erasca, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Erasca, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ERAS.
Score Composition
Financial Data
More Stock Analysis
How is the ERAS UQS Score Calculated?
The UQS (Unified Quality Score) for Erasca, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Erasca, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Erasca, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.